Phospholipids vs Triglycerides what can Be Said Responsibly
If you have spent any time comparing omega-3 supplements, you will have encountered the claim that phospholipid-bound omega-3 is "better absorbed" than triglyceride-bound omega-3. Krill oil brands lead with this. Some microalgae products hint at it.
The claim has a basis in published research, but the way it is deployed in marketing oversells a modest advantage into a decisive one. Here is what the evidence actually supports and where the responsible line falls.
What the Two Forms Are
Three fatty acid chains attached to a glycerol backbone. This is the natural structure of fat in fish, in most foods, and in standard fish oil. Your body is thoroughly adapted to digesting triglycerides.
It has been doing it for as long as you have been alive. Re-esterified triglyceride (rTG) is fish oil that was converted to ethyl ester during concentration and then converted back. We covered the label implications in our omega-3 label guide.
Phospholipid form: A fatty acid chain attached to a phosphate-containing head group. Phospholipids are the building blocks of cell membranes. In krill oil, EPA and DHA are bound to phospholipids rather than triglycerides. In whole-cell marine phytoplankton, the omega-3 exists partly within the cell's polar lipid fraction, which includes phospholipids and glycolipids.
What the Research Shows
There are published studies comparing the bioavailability of phospholipid-bound vs triglyceride-bound omega-3. Some show higher blood EPA and DHA levels from phospholipid forms. The effect sizes are typically in the range of 30 to 60% better absorption in the most favourable comparisons. That sounds impressive until you examine the details.
The studies are generally small. The comparisons are not always dose-matched (krill oil capsules typically deliver less total EPA+DHA per capsule than fish oil, so "better absorbed per milligram" can still mean "less in your bloodstream per capsule"). The duration of supplementation varies. And some studies are funded by krill oil manufacturers, which does not invalidate them but does warrant the same scrutiny we would apply to any industry-funded research.
We reviewed this literature when developing our products and our assessment is: the phospholipid absorption advantage is real, modest, and frequently overstated in marketing. It exists. It is not transformative. It does not justify paying three times the price for a product that delivers half the total EPA+DHA per serving.
What About Whole-Cell Phytoplankton
The EPA in Nannochloropsis exists within the cell's lipid structures, including polar lipids (phospholipids and glycolipids) in the cell membrane. This is a different structural context from both pure triglyceride fish oil and pure phospholipid krill oil. It is a whole-food matrix, not an extracted and concentrated oil.
Does this mean phytoplankton EPA is better absorbed? We honestly do not know with certainty. The specific bioavailability of EPA from whole-cell Nannochloropsis has not been studied in the same head-to-head comparisons that exist for krill oil vs fish oil.
Some researchers hypothesise that the polar lipid context may be favourable. We think the hypothesis is reasonable but we are not going to make a bioavailability superiority claim without the data to back it.
What we can say is: take your phytoplankton with food containing fat, and the absorption question becomes less critical. We covered all the practical absorption factors in our absorption guide.
What Can Be Said Responsibly
Here is where we draw the line for our own products and think the rest of the industry should too:
- Defensible: "Phospholipid-bound omega-3 may have modestly better bioavailability than triglyceride-bound omega-3 based on published comparisons."
- Defensible: "Whole-cell phytoplankton delivers EPA in a polar lipid matrix that differs structurally from extracted triglyceride oils."
- Not defensible: "Our product is better absorbed than fish oil" without dose-matched, independently conducted, peer-reviewed comparative data for the specific product.
- Not defensible: "Phospholipid form means you need less" unless the reduced-dose claim has been tested at the reduced dose and shown to produce equivalent blood levels.
We explain our broader approach to what can and cannot be claimed in our evidence hub. The phospholipid question is a good example of a real scientific finding being stretched past its evidence base by marketing departments who know most consumers will not read the original papers.
The Practical Takeaway on Omega-3 Lipid Form
If you are choosing an omega-3 supplement, the lipid form is a secondary consideration. The primary considerations are: does it contain enough EPA and DHA per serving to meet the EFSA intake conditions? Is it from a reputable source with batch-specific testing? Are you taking it with food? Get those right and the phospholipid vs triglyceride question becomes a refinement, not a dealbreaker.
What our research found
A network meta-analysis of 26 studies confirmed the absorption advantage, with caveats. Krill oil showed higher EPA and DHA absorption than fish oil, particularly at doses under 2,000 mg. In one study, krill oil at half the EPA+DHA dose produced equal or higher plasma levels. But the studies are small, not always dose-matched, and often industry-funded.
No clinical outcome trial has compared phospholipid omega-3 with triglyceride omega-3 head to head. The evidence is entirely about blood levels, not about whether one form produces better heart, brain, or vision outcomes than the other. Better absorption is useful. It is not proof of better clinical results. That distinction is where krill oil marketing overreaches.
Our two products sit on opposite sides of this comparison. ULTANA Phytoplankton delivers EPA in a whole-cell matrix where the lipids include polar lipid structures — closer to the phospholipid profile. Clean Omega DHA is an algae-derived oil delivering DHA in a triglyceride structure. We chose these formats because of what each species produces naturally, not to take a position in the phospholipid-vs-triglyceride debate.
Sources
- Dyerberg J, Madsen P, Moller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137-141. PubMed
- Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. Vasc Health Risk Manag. 2015;11:511-524. PubMed
- EFSA NDA Panel. Scientific Opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal cardiac function. EFSA Journal. 2010;8(10):1796. EFSA
- Arterburn LM et al. Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food. Lipids. 2007;42(11):1011-1024. PubMed
Cara Hayes, MSc Nutrition and Dietetics (University of Sydney), writes all content in the Phytality Knowledge Centre. Read our editorial policy.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult your GP or a qualified healthcare professional before starting any supplement.
Methodology and Disclosure
Phytality manufactures whole-cell phytoplankton (polar lipid matrix) and algae-derived DHA oil supplements. We have a commercial interest in lipid form being discussed but do not make bioavailability superiority claims for our specific products.
Bioavailability comparisons reflect published absorption studies including krill oil vs fish oil trials. Our assessment is editorial judgement based on the available study sizes and effect magnitudes. We have not named specific krill oil brands.
Last reviewed: March 2026
